Zilebesiran

In the past year, there have been a number of practice-changing trials and approvals for the management of hypertension.

ATLANTA — A single subcutaneous dose of zilebesiran, an investigational RNA interference agent, significantly reduced 24-hour mean ambulatory and office systolic BP at 6 months vs. placebo when added to other antihypertensive therapy.

Alnylam announced that the KARDIA-2 phase 2 trial of its novel injectable antihypertensive drug zilebesiran met its primary endpoint.

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held April 6-8 in Atlanta and online.

Promising new devices and emerging drug classes may improve BP control for some patients with difficult-to-treat hypertension, but clinicians must first address the structural inequities that impact access to care, according to a speaker.

PHILADELPHIA — Zilebesiran, an investigational subcutaneous RNA interference therapeutic, lowered systolic blood pressure at 3 months and sustained the reduction to 6 months, according to results of the phase 2 KARDIA-1 trial.

An investigational RNA interference agent targeting angiotensin demonstrated a dose-dependent, clinically significant reduction in 24-hour mean systolic BP in adults with hypertension in a phase 2 trial, according to a press release.